From Dural to Bone Grafts: DEBONE and XENOBONE for Spine Accounts

A distributor that sells collagen dural grafts to spine surgeons already has the relationships to discuss collagen bone grafts. DESU’s DEBONE and XENOBONE combine Type I bovine collagen with β-TCP and are described as bioresorbable and osteoconductive. The expansion works best when it is sequenced carefully and every intended use is confirmed against the instructions for use.

This article is for distributors and agencies that already carry, or plan to carry, DESU’s dural grafts such as DURASHEET and want to understand where DEBONE and XENOBONE might fit with spine accounts.

Why expand from dural grafts to bone grafts?

Spine surgeons use dural grafts occasionally, mainly after incidental durotomy. Bone graft materials, by contrast, are used routinely in many spine procedures, particularly those involving fusion. A distributor who has earned a spine surgeon’s trust with a dural graft has a natural opening to discuss a product that the surgeon uses far more often.

There is also a material connection. DESU’s dural grafts and bone grafts share a foundation in Type I bovine collagen, produced by the same manufacturer under the same ISO 13485 quality system. Many of the questions a hospital asks about animal-origin materials, biological evaluation and traceability will already have been answered for the dural line.

Finally, one manufacturer relationship covering several product families simplifies ordering, documentation and communication for the distributor, and gives the account a single point of contact for a wider range of needs.

There is a timing advantage as well. Spine surgeons who have evaluated a dural graft with a distributor already know how that distributor runs an evaluation: how stock is managed, how feedback is collected and how questions are answered. That experience lowers the perceived risk of evaluating a second product from the same partner.

What are DEBONE and XENOBONE?

The last row matters. On DESU’s website, XENOBONE appears within the dental product range. Before presenting either product to spine surgeons, a distributor should confirm with DESU which intended uses are described in each product’s instructions for use, and present only those. DEBONE, with its granule and sponge forms, is usually the more natural first conversation in a spine context.

What does osteoconductive mean for the surgeon?

Bone graft materials are often described by three properties. An osteoconductive material provides a scaffold on which new bone can grow. An osteoinductive material contains signals that stimulate bone formation. An osteogenic material contains living bone-forming cells, as autograft does.

DEBONE and XENOBONE are described as osteoconductive and bioresorbable. They should be presented as scaffolds, not as products that induce bone formation. β-TCP, a calcium phosphate ceramic, is widely used in bone graft substitutes, and collagen provides a familiar matrix that surgeons know from other products.

Spine surgeons are well versed in these distinctions and will expect a rep to use the terms precisely. Getting them right in the first conversation is essential for credibility.

Form matters too. Granules, sponges and particles of different sizes handle differently, and surgeons will want to know how each form is prepared and placed. The instructions for use are the reference; where they leave a question open, ask DESU rather than drawing on experience with other products.

How is selling a bone graft different from selling a dural graft?

The commercial dynamics are quite different, and a distributor should plan for that.

• Demand is planned: bone graft use is part of the surgical plan, not a contingency.
• Volume per case can be higher, and use is more frequent across the surgeon’s caseload.
• The category is crowded, with many materials and strong surgeon preferences.
• Hardware companies often offer biologics as part of their own portfolios, which raises channel questions for independent reps.
• Value analysis committees often scrutinize biologics closely because of their cumulative cost.

These differences mean that a bone graft will not sell itself on the back of a dural graft relationship. The relationship opens the door; the product still needs a clear, accurate case.

Which accounts are most promising?

Not every spine account is a good candidate for a new bone graft. The most promising accounts tend to share a few traits: surgeons who are open to discussing graft materials rather than committed to one system, an existing relationship with the distributor through the dural line, and a supply chain team interested in reviewing biologics costs.

Accounts where the surgeon’s biologics come bundled with a hardware contract are harder. That does not make them impossible, but the conversation will involve contract terms as much as product features, and it may be wiser to start elsewhere.

Teaching hospitals can be valuable for a different reason. Faculty surgeons often have detailed views on graft materials and can give precise feedback on handling and forms. That feedback is useful to the distributor and to DESU, even if adoption takes longer.

How should the expansion be sequenced?

• Establish the dural graft line first, with reliable service and at least one engaged surgeon per account.
• Confirm with DESU the intended uses, forms and documentation for DEBONE and XENOBONE in your market.
• Check agency agreements for exclusivity in biologics before presenting bone grafts.
• Identify surgeons who already discuss graft materials openly and who are interested in evaluating options.
• Propose a structured evaluation through the hospital’s normal route, as for the dural line.
• Bring handling feedback and questions back to DESU promptly.

This sequence protects the dural relationship. If the bone graft conversation goes badly because it was rushed, the distributor risks losing the trust that made it possible.

Set modest expectations for the first year. A handful of engaged surgeons evaluating DEBONE carefully is a better foundation than a broad launch that spreads the rep’s time thinly across every account in the territory.

What documentation will spine accounts expect?

For bone grafts, hospitals and surgeons typically ask for the instructions for use, product specifications by form and size, quality certificates, information on biological evaluation under the ISO 10993 series and, for bovine-derived materials, information on animal-origin controls such as those addressed by the ISO 22442 series.

Value analysis committees will also want to understand where the new product sits relative to the bone graft materials the hospital already uses. A neutral description of the material families, followed by DESU’s documented features, is more persuasive than a comparison with named products.

Much of this will be familiar from the dural graft packet. A distributor can prepare a combined supplier file for the account, with product-specific sections for each line, so that supply chain and value analysis teams see one coherent manufacturer.

Where a question goes beyond the documents the distributor holds, such as detailed resorption behavior or clinical data, the answer should come from DESU directly rather than from general knowledge about other products.

Talk to a DESU product specialist

If you already work with spine surgeons on dural grafts and want to explore whether DEBONE or XENOBONE fits your accounts, DESU’s product specialists can confirm intended uses, forms and documentation for your market. Write to sales@desu.tr, use the contact page, or request a quote.